Big Pharma’s “Black Wednesday”: Quarterly Reports Underscore Uncertainty
Executive Summary
An unprecedented string of poor third-quarter earnings reports from the top pharmaceutical companies illustrates the importance of the Medicare debate to the future of the drug industry
You may also be interested in...
J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan
Johnson & Johnson expects its pharmaceutical employee headcount to remain constant in 2004
J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan
Johnson & Johnson expects its pharmaceutical employee headcount to remain constant in 2004
Pfizer Ready To Settle Neurontin Promotion Case; Reserves $427 Mil.
Pfizer expects to pay over $400 mil. to resolve the Boston U.S. Attorney's investigation of Neurontin promotions